A detailed history of Guardian Capital Advisors LP transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Guardian Capital Advisors LP holds 1,786,414 shares of ABCL stock, worth $4.98 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares
1,786,414
Previous 1,786,414 -0.0%
Holding current value
$4.98 Million
Previous $5.29 Million 12.5%
% of portfolio
0.48%
Previous 0.6%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$9.48 - $14.52 $18.5 Million - $28.3 Million
-1,950,000 Reduced 52.19%
1,786,414 $18.1 Million
Q3 2022

Nov 14, 2022

SELL
$9.2 - $13.68 $919,999 - $1.37 Million
-100,000 Reduced 2.61%
3,736,414 $40.1 Million
Q3 2021

Nov 15, 2021

SELL
$14.85 - $21.34 $2.07 Million - $2.98 Million
-139,580 Reduced 3.51%
3,836,414 $76.8 Million
Q2 2021

Aug 17, 2021

BUY
$20.19 - $34.17 $80.3 Million - $136 Million
3,975,994 New
3,975,994 $81.4 Million

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $796M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Guardian Capital Advisors LP Portfolio

Follow Guardian Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guardian Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Guardian Capital Advisors LP with notifications on news.